| 000 | 01643 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514211949.0 | ||
| 264 | 0 | _c20061002 | |
| 008 | 200610s 0 0 eng d | ||
| 022 | _a0172-8172 | ||
| 024 | 7 |
_a10.1007/s00296-004-0544-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSarioglu, Mengu | |
| 245 | 0 | 0 |
_aComparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis. _h[electronic resource] |
| 260 |
_bRheumatology international _cJan 2006 |
||
| 300 |
_a195-200 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAlendronate _xadministration & dosage |
| 650 | 0 | 4 |
_aAlkaline Phosphatase _xblood |
| 650 | 0 | 4 |
_aAmino Acids _xblood |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aBone Density _xdrug effects |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCalcium _xblood |
| 650 | 0 | 4 |
_aCreatinine _xblood |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aEtidronic Acid _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOsteocalcin _xblood |
| 650 | 0 | 4 |
_aOsteoporosis, Postmenopausal _xdrug therapy |
| 650 | 0 | 4 | _aRisedronic Acid |
| 700 | 1 | _aTuzun, Cigdem | |
| 700 | 1 | _aUnlu, Zeliha | |
| 700 | 1 | _aTikiz, Canan | |
| 700 | 1 | _aTaneli, Fatma | |
| 700 | 1 | _aUyanik, B Sami | |
| 773 | 0 |
_tRheumatology international _gvol. 26 _gno. 3 _gp. 195-200 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00296-004-0544-z _zAvailable from publisher's website |
| 999 |
_c15265191 _d15265191 |
||